Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kagocel + valacyclovir
- Development stage
- Unknown
- Lead developer
- Nearmedic Plus
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Kagocel + valacyclovir is a combination of two antiviral agents used primarily for the treatment of herpesvirus infections, including severe herpes simplex. Kagocel is a broad-spectrum antiviral that stimulates the synthesis of interferons (types I and II), proteins that enhance the body's immune response against viral infections. It is indicated for prevention and treatment of acute respiratory viral infections, influenza, and herpes in adults[1]. Valacyclovir is an oral nucleoside analog DNA polymerase inhibitor rapidly converted to acyclovir in the body; it inhibits viral DNA replication by competitive inhibition of viral DNA polymerase, incorporation into growing viral DNA chains causing chain termination, and inactivation of the enzyme[6][7][8]. Valacyclovir is widely used to treat herpes simplex virus (HSV) types 1 and 2, varicella-zoster virus (VZV), shingles, genital herpes, cold sores, and chickenpox[2][3][4]. The combination has been studied for enhanced efficacy compared to monotherapy with either agent alone in patients with severe or recurrent herpes simplex infection[5].
- Brand names
- Valtrex
- Other names
- valaciclovir
02
Targets
Herpesvirus DNA polymerase
Beyond the preview
Go deeper on Kagocel + valacyclovir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kagocel + valacyclovir.